Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (01) : 72-77     DOI: 10.3971/j.issn.1000-8578.2022.21.0596
|
Research Progress on Immunoregulation of Chemotherapeutic Agents
LIU Zhenghao, YANG Chunguang, HU Zhiquan
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Download: PDF(2785 KB)   ( 48 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Chemotherapeutic drugs are the mainstay of treatment on mid-advanced tumors. In recent years, more and more studies have shown that chemotherapeutic drugs also have immunomodulatory effects. Some chemotherapeutic drugs can enhance anti-tumor immunity by inducing tumor cell immunogenic cell death or performing “immunogenic modulation”. In addition, chemotherapeutic drugs can also act on immune cells and even the intestinal flora. A number of clinical trials of chemotherapy combined with immune checkpoint inhibitors are currently underway. This article focuses on the immunomodulatory effect of chemotherapeu tic drugs, as well as the potential of chemotherapy combined with ICI on cancer, to provide guidance for the clinical application of chemotherapeutic drugs.
Keywords Antineoplastic; Chemotherapy; Immunomodulation; Gastrointestinal microbiome; Immune checkpoint inhibitors     
ZTFLH:  R730.53  
Issue Date: 11 January 2022
 Cite this article:   
LIU Zhenghao,YANG Chunguang,HU Zhiquan. Research Progress on Immunoregulation of Chemotherapeutic Agents[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 72-77.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.0596
http://www.zlfzyj.com/EN/Y2022/V49/I01/72
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
LIU Zhenghao
YANG Chunguang
HU Zhiquan
[1] Schirrmacher V. From chemotherapy to biological therapy: A
review of novel concepts to reduce the side effects of systemic
cancer treatment[J]. Int J Oncol, 2019, 54(2): 407-419.
[2] Mannie MD, DeOca KB, Bastian AG, et al. Tolerogenic vaccines:
Targeting the antigenic and cytokine niches of FOXP3+ regulatory
T cells[J]. Cell Immunol, 2020, 355: 104173.
[3] Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for
the definition, detection and interpretation of immunogenic cell
death[J]. J Immunother Cancer, 2019, 8(1): e000337.
[4] Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with
chemotherapy in the era of immune checkpoint inhibitors[J]. Nat
Rev Clin Oncol, 2020, 17(12): 725-741.
[5] Jones PA, Ohtani H, Chakravarthy A, et al. Epigenetic therapy in
immune-oncology[J]. Nat Rev Cancer, 2019, 19(3): 151-161.
[6] Sabbatino F, Liguori L, Polcaro G, et al. Role of Human
Leukocyte Antigen System as A Predictive Biomarker for
Checkpoint-Based Immunotherapy in Cancer Patients[J]. Int J
Mol Sci, 2020, 21(19): 7295.
[7] Gravett AM, Trautwein N, Stevanovi? S, et al. Gemcitabine alters
the proteasome composition and immunopeptidome of tumour
cells[J]. Oncoimmunology, 2018, 7(6): e1438107.
[8] Galaine J, Turco C, Vauchy C, et al. CD4 T cells target colorectal
cancer antigens upregulated by oxaliplatin[J]. Int J Cancer, 2019,
145(11): 3112-3125.
[9] Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms
of cell death: recommendations of the Nomenclature Committee
on Cell Death 2018[J]. Cell Death Differ, 2018, 25(3): 486-541.
[10] Ou W, Nam KS, Park DH, et al. Artificial Nanoscale Erythrocytes
from Clinically Relevant Compounds for Enhancing Cancer
Immunotherapy[J]. Nanomicro Lett, 2020, 12(1): 90.
[11] Huang FY, Wang JY, Dai SZ, et al. A recombinant oncolytic
Newcastle virus expressing MIP-3α promotes systemic antitumor
immunity[J]. J Immunother Cancer, 2020, 8(2): e000330.
[12] Huang X, Tang T, Zhang G, et al. Genomic investigation of
co-targeting tumor immune microenvironment and immune
checkpoints in pan-cancer immunotherapy[J]. NPJ Precis Oncol,
2020, 4(1): 29.
[13] Xu P, Liang F. Nanomaterial-Based Tumor Photothermal
Immunotherapy[J]. Int J Nanomedicine, 2020, 15: 9159-9180.
[14] Bhushan J, Radke JB, Perng YC, et al. ISG15 Connects Autophagy
and IFN-gamma-Dependent Control of Toxoplasma gondii
Infection in Human Cells[J]. mBio, 2020, 11(5): e00852-20.
[15] Miar A, Arnaiz E, Bridges E, et al. Hypoxia Induces
Transcriptional and Translational Downregulation of the Type I
IFN Pathway in Multiple Cancer Cell Types[J]. Cancer Res, 2020,
80(23): 5245-5256.
[16] Mackenzie KJ, Carroll P, Martin CA, et al. cGAS surveillance
of micronuclei links genome instability to innate immunity[J].
Nature, 2017, 548(7668): 461-465.
[17] Wu C, Du X, Tang L, et al. Schistosoma japonicum SjE16.7
Protein Promotes Tumor Development via the Receptor for
Advanced Glycation End Products (RAGE)[J]. Front Immunol,
2020, 11: 1767.
[18] Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor
4-dependent contribution of the immune system to anticancer
chemotherapy and radiotherapy[J]. Nat Med, 2007, 13(9):
1050-1059.
[19] Vacchelli E, Ma Y, Baracco EE, et al. Chemotherapy-induced
antitumor immunity requires formyl peptide receptor 1[J].
Science, 2015, 350(6263): 972-978.
[20] Di Virgilio F, Sarti AC, Falzoni S, et al. Extracellular ATP and P2
purinergic signalling in the tumour microenvironment[J]. Nat Rev
Cancer, 2018, 18(10): 601-618.
[21] Yang W, Deng H, Zhu S, et al. Size-transformable antigenpresenting
cell-mimicking nanovesicles potentiate effective cancer
immunotherapy[J]. Sci Adv, 2020, 6(50): eabd1631.
[22] Taniguchi K, Karin M. NF-κB, inflammation, immunity and
cancer: coming of age[J]. Nat Rev Immunol, 2018, 18(5): 309-324.
[23] Wu D, Zhao Z, Kim J, et al. Gemcitabine and doxorubicin in
immunostimulatory monophosphoryl lipid A liposomes for
treating breast cancer[J]. Bioeng Transl Med, 2021, 6(1): e10188.
[24] Liu P, Zhao L, Pol J, et al. Crizotinib-induced immunogenic cell
death in non-small cell lung cancer[J]. Nat Commun, 2019, 10(1):
1486.
[25] Bezu L, Sauvat A, Humeau J, et al. eIF2a phosphorylation is
pathognomonic for immunogenic cell death[J]. Cell Death Differ,
2018, 25(8): 1375-1393.
[26] Humeau J, Sauvat A, Cerrato G, et al. Inhibition of transcription
by dactinomycin reveals a new characteristic of immunogenic cell
stress[J]. EMBO Mol Med, 2020, 12(5): e11622.
[27] Hodge JW, Garnett CT, Farsaci B, et al. Chemotherapy-induced
immunogenic modulation of tumor cells enhances killing by
cytotoxic T lymphocytes and is distinct from immunogenic cell

death[J]. Int J Cancer, 2013, 133(3): 624-636.

[28] Ardiani A, Farsaci B, Rogers CJ, et al. Combination Therapy
with a Second-Generation Androgen Receptor Antagonist and a
Metastasis Vaccine Improves Survival in a Spontaneous Prostate
Cancer Model[J]. Clin Cancer Res, 2013, 19(22): 6205-6218.
[29] Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with
chemotherapy in the era of immune checkpoint inhibitors[J]. Nat
Rev Clin Oncol, 2020, 17(12): 725-741.
[30] Takeuchi S, Baghdadi M, Tsuchikawa T, et al. Chemotherapy-
Derived Inflammatory Responses Accelerate the Formation
o f I m m u n o s u p p r e s s i v e M y e l o i d C e l l s i n t h e Ti s s u e
Microenvironment of Human Pancreatic Cancer[J]. Cancer Res,
2015, 75(13): 2629-2640.
[31] Wesolowski R, Duggan MC, Stiff A, et al. Circulating myeloidderived
suppressor cells increase in patients undergoing neoadjuvant
chemotherapy for breast cancer[J]. Cancer Immunol,
Immunother, 2017, 66(11): 1437-1447.
[32] Ahmad I, Valverde A, Naqvi RA, et al Long Non-coding RNAs
RN7SK and GAS5 Regulate Macrophage Polarization and Innate
Immune Responses[J]. Front Immunol, 2020, 11: 604981.
[33] Nakamura K, Smyth MJ. Myeloid immunosuppression and
immune checkpoints in the tumor microenvironment[J]. Cell Mol
Immunol, 2020, 17(1): 1-12.
[34] McDonnell AM, Lesterhuis WJ, Khong A, et al. Tumor-infiltrating
dendritic cells exhibit defective cross-presentation of tumor
antigens, but is reversed by chemotherapy[J]. Eur J Immunol,
2015, 45(1): 49-59.
[35] 罗佳, 金锋. 肠道菌群影响宿主行为的研究进展[J]. 科学通报,
2014, 59(22): 2169-2190. [Luo J, Jin F. Research progress on the
influence of intestinal flora on host behavior[J]. Ke Xue Tong
Bao, 2014, 59(22): 2169-2190.]
[36] Trivieri N, Pracella R, Cariglia MG, et al. BRAFV600E mutation
impinges on gut microbial markers defining novel biomarkers for
serrated colorectal cancer effective therapies[J]. J Exp Clin Cancer
Res, 2020, 39(1): 285.
[37] Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome
modulates response to anti-PD-1 immunotherapy in melanoma
patients[J]. Science, 2018, 359(6371): 97-103.
[38] Yang Y, Luo M, Zhang K, et al. Nedd4 ubiquitylates VDAC2/3
to suppress erastin-induced ferroptosis in melanoma[J]. Nat
Commun, 2020, 11(1): 433.
[39] Weber J. Immune Checkpoint Proteins: A New Therapeutic
Paradigm for Cancer Preclinical Background: CTLA-4 and PD-1
Blockade[J]. Semin Oncol, 2010, 37(5): 430-439.
[40] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and
Immune Correlates of Anti-PD-1 Antibody in Cancer[J]. N Engl J
Med, 2012, 366(26): 2443-2454.
[41] Leduc C, Adam J, Louvet E, et al. TPF induction chemotherapy
increases PD-L1 expr‍ession in tumour cells and immune cells in
head and neck squamous cell carcinoma[J]. ESMO Open, 2018,
3(1): e000257.
[42] Gu Z, Wang Q, Shi Y, et al. Nanotechnology-mediated
immunochemotherapy combined with docetaxel and PD-L1
antibody increase therapeutic effects and decrease systemic
toxicity[J]. J Control Release, 2018, 286: 369-380.

Related articles from Frontiers Journals
[1] FENG Qingyan, XU Jinsheng, BAI Yaling. Progress of Antiangiogenic Drug-induced Renal Injury[J]. Cancer Research on Prevention and Treatment, 2021, 48(04): 424-428.
[2] WANG Chun, YU Lixia, WANG Lifeng, QIAN Hanqing, YAN Yingci, WANG Xinyue, LI Rutian. Cisplatin-loaded mPEG-PCL Nanoparticles: Relation of PEG-PCL/PCL Hybrid Proportions and Antitumor Activity in Vitro[J]. Cancer Research on Prevention and Treatment, 2020, 47(06): 411-415.
[3] HE Yang, YANG Runfeng, ZHOU Yingying, XU Qian, YAN Hao, JIANG Lei, JIANG Xiaohui, HUANG Yi. Effect of Aprepitant on Chemotherapy-induced Adverse Reactions in Gynecological Malignancy Patients[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 913-916.
[4] ZHANG Hao, WU Tingting, LI Ying, XU Hongbin. Dexamethasone for Chemotherapy-induced Diarrhea: A Case Report and Literature Review[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 938-940.
[5] HOU Wenjie, XU Jianying, CHI Chi, MAO Min, ZHANG Yueming, CHEN Youguo. Comparison of Efficacy and Safety Between Liposome-paclitaxel plus Carboplatin and Paclitaxel plus Carboplatin on Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(06): 410-413.
[6] LI Daojun, XU Xinhua, ZHANG Jianyu, LI Cong. Clinical Observation of Olanzapine in Treatment of Nausea and Vomiting Caused by Opioid Analgesics[J]. Cancer Research on Prevention and Treatment, 2018, 45(05): 326-328.
[7] QI Xiaoguang, QI Chunyan, QIN Boyu, WANG Lijie, HU Yi. Comparison of Different Time Nutritional Intervention on Chemotherapy-induced IV Degree Myelosuppression in Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2018, 45(01): 29-31.
[8] CHEN Yu, WU Weili, JIN Feng, LI Yuanyuan, LONG Jinhua, GONG Xiuyun, CHEN Xiaoxiao, HUANG Shiying, ZHOU Ya, TANG Hong. Clinical Observation of Induction Chrono-chemotherapy Followed by Concurrent Lobaplatin Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2017, 44(10): 689-693.
[9] DONG Shuang, WANG Jun, HU Sheng, LIAO Guoxiang, RAN Fengming. Aprepitant versus Olanzapine for Prevention of Nausea and Vomiting Induced by Multiday Chemotherapy in Female Lung Cancer or Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(05): 356-359.
[10] YU Jing, ZHANG Huifeng, LEI Dansheng. Clinical Value of Pharmacokinetic Monitoring of Serum Paclitaxel Concentration in Paclitaxel-based Chemotherapy on Patients with Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2017, 44(04): 268-271.
[11] ZHAO Shuangshuang, ZHAO Yu, LI Li, XU Qing. Influence of Peripherally Inserted Central Venous Catheters on Plasma D-dimer Level in Chemotherapy Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(02): 124-128.
[12] YANG Yuanyuan, LU Yang, ZHANG Xiaolong, ZHANG Qing, LI Zhenzhen, ZHANG Yanjun. Inhibition Effect of Ad-IL24 Combined with Low Dose of 5-Fu on Hepatocarcinoma Cells HepG2 and Its Mechanism[J]. Cancer Research on Prevention and Treatment, 2016, 43(12): 1030-1034.
[13] ZHANG Xiufen, LIU Beibei, GUO Zijian, LI Lihua. UGCG is Involved in Oxaliplatin Resistance Mechanism of Human Colon Cancer Through Regulating MDR1/P-gp Expression[J]. Cancer Research on Prevention and Treatment, 2016, 43(09): 743-747.
[14] XU Hong, MEI Jiazhuan, LI Ruijun, ZHAO Jizhi. Killing Effect of Paclitaxel and Cisplatin on EGFR-wild and Mutant Lung Adenocarcinoma Cells and Related Molecular Mechanism[J]. Cancer Research on Prevention and Treatment, 2016, 43(03): 197-200.
[15] CHENG Daohai, LU Hua, HUANG Zhenguang, QIN Xingkun. Influence of Drug Combinations on High-dose Methotrexate-induced Nephrotoxicity and Blood Concentrations of Childhood Acute Lymphoblastic Leukemia[J]. Cancer Research on Prevention and Treatment, 2015, 42(11): 1148-1151.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed